Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Zinzani PL, Tani M, Pulsoni A, Gobbi M, Perotti A, De Luca S, Fabbri A, Zaccaria A, Voso MT, Fattori P, Guardigni L, Ronconi S, Cabras MG, Rigacci L, De Renzo A, Marchi E, Stefoni V, Fina M, Pellegrini C, Musuraca G, Derenzini E, Pileri S, Fanti S, Piccaluga PP, Baccarani M. Zinzani PL, et al. Among authors: musuraca g. Lancet Oncol. 2008 Apr;9(4):352-8. doi: 10.1016/S1470-2045(08)70039-1. Epub 2008 Mar 14. Lancet Oncol. 2008. PMID: 18342572 Clinical Trial.
Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results.
Ghia P, Pluta A, Wach M, Lysak D, Šimkovič M, Kriachok I, Illés Á, de la Serna J, Dolan S, Campbell P, Musuraca G, Jacob A, Avery EJ, Lee JH, Usenko G, Wang MH, Yu T, Jurczak W. Ghia P, et al. Among authors: musuraca g. Hemasphere. 2022 Nov 14;6(12):e801. doi: 10.1097/HS9.0000000000000801. eCollection 2022 Dec. Hemasphere. 2022. PMID: 36398134 Free PMC article.
How I Manage Chronic Lymphocytic Leukemia.
Nasnas P, Cerchione C, Musuraca G, Martinelli G, Ferrajoli A. Nasnas P, et al. Among authors: musuraca g. Hematol Rep. 2023 Aug 1;15(3):454-464. doi: 10.3390/hematolrep15030047. Hematol Rep. 2023. PMID: 37606492 Free PMC article. Review.
Correction: Bocci et al. Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma. J. Clin. Med. 2022, 11, 7162.
Bocci G, Pelliccia S, Orlandi P, Caridi M, Banchi M, Musuraca G, Di Napoli A, Bianchi MP, Patti C, Anticoli-Borza P, Battistini R, Casaroli I, Lanzolla T, Tafuri A, Cox MC. Bocci G, et al. Among authors: musuraca g. J Clin Med. 2023 Nov 13;12(22):7053. doi: 10.3390/jcm12227053. J Clin Med. 2023. PMID: 38002810 Free PMC article.
Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon.
Martino M, Naso V, Loteta B, Canale FA, Pugliese M, Alati C, Musuraca G, Nappi D, Gaimari A, Nicolini F, Mazza M, Bravaccini S, Derudas D, Martinelli G, Cerchione C. Martino M, et al. Among authors: musuraca g. Int J Mol Sci. 2022 Nov 1;23(21):13332. doi: 10.3390/ijms232113332. Int J Mol Sci. 2022. PMID: 36362130 Free PMC article. Review.
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience.
Zinzani PL, Tani M, Gabriele A, Gherlinzoni F, De Vivo A, Ricci P, Bandini G, Lemoli RM, Motta MR, Rizzi S, Guidice V, Zompatori M, Stefoni V, Alinari L, Musuraca G, Marchi E, Bassi S, Conte R, Pileri S, Tura S, Baccarani M. Zinzani PL, et al. Among authors: musuraca g. Leuk Lymphoma. 2004 Feb;45(2):321-6. doi: 10.1080/10428190310001597900. Leuk Lymphoma. 2004. PMID: 15101718
100 results